Significance: Cardiac troponin I (cTnI) is a primary biomarker for diagnosis of myocardial infarction (MI). In contrast to central laboratory tests for cTnI, point-of-care (POC) testing has the advantage of providing results when the patient is first encountered, which helps high-risk patients to be treated more rapidly and low-risk patients to be released in a timely fashion. A paper fluidic platform is good for POC testing because the paper is abundant, low cost, and disposable. However, current cTnI assays on paper platforms use antibodies as the recognition element, which has limitations due to the high cost of production and antibody stability issues at the POC.
Aim: To develop an aptamer-based assay on a paper strip using surface-enhanced resonance Raman spectroscopy (SERRS) for detection of cTnI in the clinically relevant range at the POC.
Approach: Gold nanoparticles (AuNPs) were functionalized with a Raman reporter molecule, malachite green isothiocyanate. The functionalized AuNPs were encapsulated in a silica shell and provided a SERRS signal using a handheld Raman system with a 638-nm excitation wavelength. A primary aptamer and a secondary aptamer of cTnI were used in a sandwich assay format to bind the cTnI on a test line of a paper fluidic platform. By measuring the SERRS signal from the test line, the concentration of cTnI was quantitatively determined.
Results: The aptamer-based SERRS assay on a paper strip had a detection range of 0.016 to 0.1 ng / ml for cTnI, had good selectivity for cTnI compared to three other markers, had good stability over 10 days, and had good performance in the more complex serum sample matrix.
Conclusions: The aptamer-based SERRS assay on a paper strip has the potential to provide a sensitive, selective, stable, repeatable, and cost-effective platform for the detection of cTnI toward eventual use in diagnosis of MI at the POC.
The accurate and rapid diagnosis of myocardial infarction (MI) is essential to implement timely and definitive treatment to the patient. Cardiac Troponin I (cTnI) has been widely used as a biomarker for early diagnosis of MI. Point-of-care (POC) testing is favored because it can provide timely results when the patient is first encountered (e.g. ambulance, clinic, or emergency department). However, the clinical cut-off of cTnI for diagnosis of MI is in the pico- to femtomolar range (i.e. 0.01-0.1 ng/ml). Thus, a sensitive sensing system is needed to quantitively measure cTnI at the POC. Surface-enhanced Raman spectroscopy (SERS) is a sensitive optical technique that can be used to measure trace analytes in a sample. Moreover, paper-based sensing systems have demonstrated potential as a platform to implement assays, especially at the POC. This research describes the development of a paper-based SERS assay for detection of cTnI in the physiological relevant range. Aptamer is used in the assay for recognizing the cTnI in a sample. SERS is used to sensitively transduce the sensing signal from the assay. A handheld Raman spectrometer is used to measure the SERS signal. By measuring the change in the SERS signal, the concentration of target molecule is quantitatively determined. Moreover, spectral processing techniques are used to evaluate their effect on signal-to-noise ratio as well as sensitivity of the assay. Results showed the designed sensing system can be used to measure cTnI (0-0.5 ng/mL) in standard buffer solutions.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.